| 18.79 -0.09 (-0.48%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.92 | 1-year : | 26.77 |
| Resists | First : | 19.62 | Second : | 22.92 |
| Pivot price | 18.74  |
|||
| Supports | First : | 17.79 | Second : | 16.65 |
| MAs | MA(5) : | 18.76 |
MA(20) : | 18.46 |
| MA(100) : | 18 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 62 |
D(3) : | 62 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 22.5 | Low : | 14.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDWD ] has closed below upper band by 46.8%. Bollinger Bands are 36.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.92 - 19.03 | 19.03 - 19.13 |
| Low: | 18.23 - 18.35 | 18.35 - 18.46 |
| Close: | 18.62 - 18.81 | 18.81 - 18.98 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Wed, 24 Dec 2025
MediWound Ltd. (NASDAQ:MDWD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Fri, 19 Dec 2025
MediWound Ltd. (NASDAQ:MDWD) is a favorite amongst institutional investors who own 52% - Yahoo Finance
Wed, 17 Dec 2025
MediWound (NASDAQ:MDWD) Stock Passes Above 50-Day Moving Average - What's Next? - MarketBeat
Wed, 10 Dec 2025
MediWound Announces Promising Clinical Data for NexoBrid® in Reducing Traumatic Tattoos from Blast and Abrasion Injuries - Quiver Quantitative
Fri, 21 Nov 2025
MediWound Ltd. (NASDAQ:MDWD) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 20 Nov 2025
MediWound Ltd (MDWD) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 15.1 (%) |
| Held by Institutions | 53.6 (%) |
| Shares Short | 981 (K) |
| Shares Short P.Month | 1,010 (K) |
| EPS | -1.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.91 |
| Profit Margin | -98.5 % |
| Operating Margin | -120.2 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -48.9 % |
| Qtrly Rev. Growth | 24.7 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -10.22 |
| PEG Ratio | 0 |
| Price to Book value | 4.8 |
| Price to Sales | 11.5 |
| Price to Cash Flow | -16.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|